Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.

It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.

Zhitong FinanceDec 16, 2024 14:45

Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15, 2024 12:17

Research Report Mining丨Kaiyuan Securities: Initiates a "Buy" rating for Nanjing King-Friend Biochemical Pharmaceutical, as biosimilars enter a harvest period.

On December 11, Gelonghui reported that Kaiyuan Securities' Research Reports pointed out that Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) covers Active Pharmaceutical Ingredient of heparin, heparin formulations, sterile injections, CDMO, and biological drugs. In recent years, it has vigorously promoted the layout and expansion of biological Innovative Drugs and high-end generic products. As the company's layout of biosimilars gradually gets approved, it is expected to bring significant performance elasticity. Considering the company's gradual expansion in the USA injectable market channels and the layout of biosimilars, it is estimated that the net income attributable to parent company from 2024 to 2026 will be 0.859/1.177/1.679 billion yuan, with the current stock price corresponding to PEs of 26.6.

Gelonghui FinanceDec 11, 2024 14:29 · Ratings

Nanjing King-Friend Biochemical Pharmaceutical (603707): An international injection platform company, biosimilars are entering a harvest period.

The international injection platform company is entering a harvest period with its biosimilars. The company's business encompasses active pharmaceutical ingredients for heparin, heparin formulations, sterile injectables, CDMO, and biologics, and in recent years, it has vigorously promoted the layout and expansion of innovative drugs and high-end generic products.

Open Source SecuritiesDec 10, 2024 14:47

Nanjing King-Friend Biochemical Pharmaceutical Gets US FDA Registration Approval for Vitamin B12 Injection

MT NewswiresNov 19, 2024 13:28

Express News | Nanjing King-Friend Biochemical Pharmaceutical: Vitamin B12 injection has been approved by the usa FDA.

BreakingsNov 18, 2024 17:26